Earlier this week, the Federal Trade Commission dropped its allegation that AbbVie’s (formerly Abbott Laboratories) had improperly blocked generic competition for its testosterone medication AndroGel in 2011 through sham litigation.
However, an official noted that existing rules do not support the agency’s efforts to reclaim money for customers.Consumers who were harmed by AbbVie’s and Besin’s anticompetitive behavior will not be compensated, according to Holly Vedova, interim head of the Bureau of Competition.
As a result, Mendoza said, the FTC has to reinstate Section 13(b) of the FTC Act, which allows the agency to seek compensation for consumers in competition disputes.The Federal Trade Commission (FTC) has taken action against pharmaceutical corporations on a number of occasions for engaging in “sham” patent litigation, which it claims is used to delay generic competitors by tying them up in court.
Be First to Comment